NIKKEI 225
38,428.83 -406.27 (-1.05%) HANG SENG
18,530.95 +51.58 (+0.28%) CRUDE OIL
78.06 -0.32 (-0.41%) GOLD FUTURES
2,316.10 -8.10 (-0.35%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,186.20 -876.89 (-1.72%)
Rigel Pharmaceuticals, Inc. (RIGL)
After hours:
| Previous close | 1.2200 |
| Open | 1.2300 |
| Bid | 1.1800 x 600 |
| Ask | 1.2100 x 800 |
| Day's range | 1.1900 - 1.2587 |
| 52-week range | 0.7100 - 1.9600 |
| Volume | |
| Avg. volume | 1,504,816 |
| Market cap | 208.732M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.57 |
ZacksRigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireRigel Reports First Quarter 2024 Financial Results and Provides Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA® (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitr
ZacksProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
